logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Y

Yeonjung Jo

Utah System of Higher Education
H指数:9
被引数:603

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy

接受强化雄激素剥夺治疗的转移性激素敏感性前列腺癌患者生存的基因组生物标志物

PROSTATE CANCER AND PROSTATIC DISEASES
IF5.8
2025-01-310
PRE
Gebrael, Georges; Sayegh, Nicolas; Chehade, Chadi Hage; Jo, Yeonjung; Narang, Arshit; Chigarira, Beverly; Tripathi, Nishita; Srivastava, Ayana; Tandar, Clara; Williams, Jessica F.; Garg, Diya; Ji, Richard; Maughan, Benjamin L.; Swami, Umang; Agarwal, Neeraj
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216

体重指数与转移性激素敏感性前列腺癌患者总生存期的相关性：SWOG-1216患者层面数据分析

European Urology Oncology
IF9.3
2024-11-010
PRE
Umang Swami; Yeonjung Jo; Arshit Narang; Melissa Plets; Chadi Hage Chehade; Georges Gebrael; Shilpa Gupta; Zin Myint; Catherine Tangen; Primo N. Lara; Ian M. Thompson; Maha H.A. Hussain; Tanya B. Dorff; Seth P. Lerner; Neeraj Agarwal
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone- sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

3个月和7个月的前列腺特异性抗原水平可作为转移性激素敏感性前列腺癌总生存期的预后指标: SWOG S1216的结果，这是一项雄激素剥夺加Orteronel或比卡鲁胺的3期随机试验

EUROPEAN UROLOGY ONCOLOGY
IF9.3
2024-10-012
OA
Parikh, Mamta; Tangen, Catherine; Hussain, Maha H. A.; Gupta, Shilpa; Callis, Sam; Jo, Yeonjung; Harzstark, Andrea; Paller, Channing J.; George, Saby; Zibelman, Matthew R.; Cheng, Heather H.; Maughan, Benjamin L.; Zhang, Jingsong; Pachynski, Russell K.; Bryce, Alan H.; Lin, Daniel W.; Quinn, David I.; Lerner, Seth P.; Thompson, Ian M.; Dorff, Tanya B.; Lara, Primo N.; Agarwal, Neeraj
Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor
CANCER
IF5.1
2024-04-020
OAAI
Gebrael, Georges; Jo, Yeonjung; Thomas, Vinay Mathew; Li, Haoran; Sayegh, Nicolas; Tripathi, Nishita; Srivastava, Ayana; Nordblad, Blake; Dal, Emre; Narang, Arshit; Brundage, James; Campbell, Patrick; Fortuna, Gliceida Galarza; Chehade, Chadi Hage; Maughan, Benjamin L.; Agarwal, Neeraj; Swami, Umang
Tumor genomic and transcriptomic profiling of patients (pts) with metastatic castration sensitive prostate cancer (mCSPC) who do versus do not achieve an optimal PSA response to androgen deprivation therapy intensification (ADTi)
CANCER RESEARCH
IF16.6
2024-03-220
PRE
Thomas, Vinay Mathew; Chigarira, Beverly; Gebrael, Georges; Chehade, Chadi; Narang, Arshit; Sayegh, Nicolas; Tripathi, Nishita; Jo, Yeonjung; Tandar, Clara; Srivastava, Ayana; Ji, Richard; Dal, Emre; Fortuna, Gliceida Galarza; Li, Haoran; Maughan, Benjamin L.; Swami, Umang; Agarwal, Neeraj
Comparative real-world effectiveness of PD-1/L1 inhibitor (PD-1i) plus cabozantinib (cabo) vs cabo after progression with prior immune checkpoint inhibitor (ICI) treatment (Rx) in metastatic clear cell renal cell carcinoma (mccRCC)
ANNALS OF ONCOLOGY
IF65.4
2023-10-010
OA
Swami, U.; Jo, Y. Jung; Thomas, V. Mathew; Gebrael, G.; Li, H.; Sayegh, N.; Tripathi, N.; Srivastava, A.; Nordblad, B.; Dal, E.; Brundage, J.; Campbell, P.; Fortuna, G. Galarza; Chehade, C. Hage; Maughan, B. L.; Agarwal, N.
Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab plus nivolumab (ipi plus nivo) vs. PD-1/L1 inhibitor (PDI) plus tyrosine kinase inhibitor (TKI)
ANNALS OF ONCOLOGY
IF65.4
2023-10-010
PRE
Gebrael, G.; Jo, Y. Jung; Thomas, V. Mathew; Li, H.; Fortuna, G. Galarza; Sahu, K.; Sayegh, N.; Tripathi, N.; Chigarira, B.; Srivastava, A.; Chehade, C. Hage; Nordblad, B.; Dal, E.; Brundage, J.; Maughan, B. L.; Agarwal, N.; Swami, U.
Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA
FRONTIERS IN ONCOLOGY
IF3.3
2022-09-152
OAAI
Swami, Umang; Zimmerman, Raquel Mae; Nussenzveig, Roberto H.; Hernandez, Edgar Javier; Jo, Yeonjung; Sayegh, Nicolas; Wesolowski, Sergiusz; Kiedrowski, Lesli A.; Barata, Pedro C.; Lemmon, Gordon Howard; Bilen, Mehmet A.; Heath, Elisabeth I.; Nandagopal, Lakshminarayan; Babiker, Hani M.; Pal, Sumanta K.; Lilly, Michael; Maughan, Benjamin L.; Haaland, Benjamin; Yandell, Mark; Sartor, Oliver; Agarwal, Neeraj

研究方向

暂未获取到该数据
N
Neeraj Agarwal
H 指数:6论文数:45被引数:590
U
Umang Swami
H 指数:27论文数:417被引数:3,159
B
Benjamin L. Maughan
H 指数:29论文数:393被引数:3,286
N
Nicolas Sayegh
H 指数:17论文数:199被引数:1,866
G
Georges Gebrael
H 指数:10论文数:146被引数:464
C
Chadi Hage Chehade
H 指数:7论文数:101被引数:165
N
Nishita Tripathi
H 指数:13论文数:126被引数:559
G
Gliceida Galarza Fortuna
H 指数:8论文数:92被引数:286
B
Beverly Chigarira
H 指数:5论文数:75被引数:184
A
Ayana Srivastava
H 指数:3论文数:30被引数:45